米哚妥林

Mirdametinib

Abstract

No information is available on the clinical use of mirdametinib during breastfeeding. Because mirdametinib is over 99% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed, the manufacturer recommends that breastfeeding be discontinued during mirdametinib therapy and for 1 week after the last dose.

摘要

关于米哚妥林在哺乳期的临床应用尚无可用信息。由于米哚妥林与血浆蛋白的结合率超过99%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿的潜在毒性，制造商建议在米哚妥林治疗期间及最后一剂后1周内停止母乳喂养。